Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.
BACKGROUND Studies indicate that myeloperoxidase ( MPO ) is associated with disease progression and severity in heart failure ( HF ) , while it may provide a mechanistic link between inflammation and adverse cardiac remodeling . The mechanisms that regulate MPO are unclear , while it is unknown whether specific treatments such as HMG-CoA reductase inhibitors and xanthine oxidase inhibitors may modify MPO . Therefore in the present study we examined the effects of rosuvastatin and allopurinol on MPO levels in patients HF . METHODS Sixty clinical ly stable patients with systolic HF were r and omized to receive rosuvastatin 10mg/day , allopurinol 300mg/day or placebo and followed up for 1 month . Plasma levels of MPO and serum levels of soluble CD40 lig and , interleukin-6 , and oxidized LDL were determined using ELISA . All measurements were made before and after 1-month treatment . RESULTS Rosuvastatin significantly reduced plasma levels of MPO ( p=0.003 ) , which remained unchanged in the other groups . Furthermore , the change of MPO levels in the rosuvastatin-treated group was significantly different compared with the other groups ( p<0.05 ) . Rosuvastatin administration also led to a significant decrease in oxidized LDL ( p=0.009 ) , while the other inflammatory markers remained unchanged in all groups . In the total population , a significant correlation was observed between the baseline levels of MPO and hsCRP ( r=0.275 , p=0.027 ) , fibrinogen ( r=0.278 , p=0.025 ) , and sCD40L ( r=0.288 , p=0.021 ) . CONCLUSIONS Short-term treatment with rosuvastatin regulates inflammatory process in patients with heart failure by significantly reducing plasma levels of MPO . This finding reveals a novel pleiotropic effect of statins in patients with heart failure , and provides further insights into the pathophysiological mechanisms of MPO in heart failure
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .